Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | AGXT | P21549 | 6/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 4/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1019025 | 0.83 | LOXL2 (0.72) | FFAR1PDPK1CARM1PRMT1LOXL2 | |
| SCHEMBL5016046 | 0.82 | LOXL2 (0.66) | PDPK1AGXTCARM1PRMT1LOXL2 | |
| SCHEMBL14074962 | 0.81 | FFAR1 (0.53) | FFAR1PDPK1CARM1PRMT1LOXL2 | |
| SCHEMBL5216533 | 0.80 | LOXL2 (0.58) | FFAR1PDPK1CARM1PRMT1LOXL2 | |
| SCHEMBL18313516 | 0.80 | PDPK1 (0.59) | FFAR1PDPK1CARM1PRMT1LOXL2 | |
| SCHEMBL18586399 | 0.80 | PDPK1 (0.59) | FFAR1PDPK1CARM1PRMT1LOXL2 | |
| SCHEMBL9454664 | 0.80 | PDPK1 (0.59) | FFAR1PDPK1CARM1PRMT1LOXL2 | |
| SCHEMBL12747050 | 0.80 | PDPK1 (0.59) | FFAR1PDPK1CARM1PRMT1LOXL2 | |
| SCHEMBL30807257 | 0.79 | FFAR1 (0.51) | FFAR1PDPK1CARM1PRMT1LOXL2 | |
| SCHEMBL10336939 | 0.78 | PDPK1 (0.68) | FFAR1PDPK1CARM1PRMT1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419962-B2 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| CN-101107000-A | 3,6-bicyclolides | ENANTA PHARM INC (US) | 2008-01-16 | — | — | CN | disclosed |
| EP-1830858-A2 | 3, 6-BICYCLOLIDES | Enanta Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142214-A1 | 3,6-bicyclolides | ENANTA PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006063039-A2 | 3, 6-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142214-A1 | 3,6-bicyclolides | ABCB11, CYP2B6, CYP3A7 | FFAR1 1814/4885PDPK1 1677/4885AGXT 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.